The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China

Abstract

The 2017 medication price negotiation and reimbursement policy decreased targeted medication procurement costs per DDD, increased volumes procured and at least temporarily contained spending. These changes should result in better access to and affordability of targeted anticancer medications in China.